- Home
- NRXS vs NOTV Comparison
NRXS vs NOTV Comparison
Compare NRXS & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | NOTV |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 29.9M |
| IPO Year | 2023 | 1997 |
Fundamental Metrics
Financial Performance| Metric | NRXS | NOTV |
|---|---|---|
| Price | $2.67 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.00 | $3.00 |
| AVG Volume (30 Days) | 62.2K | ★ 1.6M |
| Earning Date | 11-10-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,362,320.00 | ★ $513,024,000.00 |
| Revenue This Year | $31.05 | $6.26 |
| Revenue Next Year | $137.61 | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | 4.54 |
| 52 Week Low | $1.33 | $0.66 |
| 52 Week High | $6.20 | $6.48 |
Technical Indicators
Market Signals| Indicator | NRXS | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 36.67 |
| Support Level | $2.65 | $0.84 |
| Resistance Level | $2.82 | $0.95 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 74.21 | 39.36 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.